Clinical Trials Logo

Filter by:
NCT ID: NCT06326996 Not yet recruiting - Clinical trials for Coronary Heart Disease

Thiamine Intervention and Coronary Artery Bypass Grafting

B1&CABG
Start date: May 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.

NCT ID: NCT06326983 Recruiting - Pain Clinical Trials

Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery

Start date: May 9, 2024
Phase: N/A
Study type: Interventional

This is a prospective, randomized, controlled, non-inferiority study of patients undergoing tonsil surgeries at Boston Children's Hospital Waltham. The overall aim is to evaluate the efficacy of an opioid anesthetic plan (morphine, ketorolac, and acetaminophen versus an opioid sparing anesthetic plan (dexmedetomidine, ketorolac and acetaminophen) for perioperative analgesia and recovery time in patients undergoing tonsillectomies and tonsillotomies at Boston Children's Hospital Waltham. Secondary measures include rescue opioids administered in post-anesthesia care unit (PACU), re-operation secondary to bleeding, emergence delirium, post-operative nausea and vomiting, intraoperative hemodynamics, intraoperative vasopressor administration, and length of procedure.

NCT ID: NCT06326931 Completed - Clinical trials for Meibomian Gland Dysfunction

Thermal Pulsation Versus Warm Compress Treatment for Meibomian Gland Dysfunction

Start date: June 24, 2022
Phase: Phase 4
Study type: Interventional

This study aimed to assess the treatment outcome differences between a single, in-office bilateral treatment with the thermal pulsation system and twice-daily, 10-minute applications of the warm compress mask at home for 8 weeks.

NCT ID: NCT06326905 Not yet recruiting - Depression Clinical Trials

CAPABLE Transplant

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this mixed methods study is to adapt CAPABLE as CAPABLE Transplant to accomplish two things: 1) To resolve barriers to being classified as active on the Kidney Transplant (KT) waitlist and 2) as a surgical prehabilitation intervention targeting the pre-frail/ frail KT waitlist population. It consists of two phases- an open label pilot and a randomized waitlist control trial.

NCT ID: NCT06326814 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Start date: October 11, 2021
Phase: Phase 1
Study type: Interventional

Primary objective - The tolerability and safety of SAR443809 Secondary - The PK parameters of SAR443809 - The PD activity of SAR443809 - The immunogenicity of SAR443809

NCT ID: NCT06326684 Recruiting - Clinical trials for Alcohol Use Disorder

Suvorexant and Alcohol

Start date: June 7, 2024
Phase: Early Phase 1
Study type: Interventional

This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of alcohol in humans. As such, the outcomes will contribute to our understanding of the clinical neurobiology of Alcohol Use Disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on alcohol addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.

NCT ID: NCT06326645 Not yet recruiting - Clinical trials for Short Bowel Syndrome

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

Start date: December 1, 2024
Phase: Early Phase 1
Study type: Interventional

The objectives of this study are to evaluate the efficacy and safety of crofelemer treatment in adults affected by Short Bowel Syndrome (SBS) with an ileostomy on parenteral support (PS) in reducing output or PS needs. Crofelemer will be provided as a powder three times daily for 12 weeks and a 4 week follow up. .

NCT ID: NCT06326567 Recruiting - Cancer Clinical Trials

Comprehensive Connected Cancer Care (C4): Intervention Evaluation

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services.

NCT ID: NCT06326463 Recruiting - Lymphoma Clinical Trials

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

Start date: July 2024
Phase: Phase 1
Study type: Interventional

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies after lymphodepleting chemotherapy. Secondary Objectives To evaluate the antileukemic activity of CD70-CAR T cells. We will determine the anti- leukemic activity of the CD70-CAR T cells in the bone marrow and in the treatment of extramedullary disease.

NCT ID: NCT06326424 Not yet recruiting - Dementia Clinical Trials

Delirium Identification in Older Patients With Alzheimer's and Other Related Dementias In the Emergency Department

DELIRIUM
Start date: April 10, 2024
Phase:
Study type: Observational

Delirium is highly prevalent and very bad for patients with dementia. Delirium is a dangerous medical condition that occurs in 6-38% of older Emergency Department patients and 70% of ICU patients. A person who develops delirium in the ED or hospital has a 12 times higher odds of being newly diagnosed with dementia in the next year compared to a similar patient who does not become delirious. Delirium is especially dangerous for persons living with Alzheimer Disease and Related Dementias (AD/ADRD). Persons living with ADRD have an almost 50% chance of developing delirium in the hospital. Clinicians are bad at recognizing delirium. A recent systematic review led by the Geriatric Emergency Care Applied Research network (NIH funded) found that current delirium screening tools are at most 64% sensitive, meaning that physicians can identify some phenotypes of delirium well, but cannot easily rule out delirium in acutely ill older patients. The investigators propose integrating wrist biosensors into the emergency management of older adults with dementia. The investigators will monitor heart rate variability, movement, and electrodermal activity (electrical activity of at the level of the skin) to determine if an array of biosensors more sensitive to delirium than current verbal screening tools.